-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
-
Summary
-
SAB Biotherapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q4 2020 to Q2 2024.
- SAB Biotherapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending June 30, 2024 was -$7.34M, a 6.61% decline year-over-year.
- SAB Biotherapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending June 30, 2024 was -$40.3M, a 38.2% decline year-over-year.
- SAB Biotherapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$42.2M, a 125% decline from 2022.
- SAB Biotherapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$18.7M, a 9.31% decline from 2021.
- SAB Biotherapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$17.1M, a 185% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)